1454 results about "Bacteriophage" patented technology

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.

The instant specification provides for evolved base editors which overcome deficiencies of those in art (including increased efficiency and / or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system. In particular, the instant specification provides for evolved cytidine base editors (e.g., based on APOBEC1, CDA, or AID cytidine deaminase domains) which overcome deficiencies of those in art (including increased efficiency and / or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system.

The invention discloses a preparation method and application of a universal renewable immunoaffinity magnetic bead, and belongs to the technical field of chemical detection.The preparation method comprises the steps that firstly, an engineered bacteriophage H6G5-M13 is constructed, then a polypeptide module is coupled to the engineered bacteriophage H6G5-M13, the polypeptide module comprises a part A, a part B and a part C from the N end to the C end, the part A is a target object recognition sequence located at the N end, and the part C is a target object recognition sequence located at the C end; the part B is a selectively added connecting sequence, the part C is an LPXTG substrate sequence and is located at the C end, and X refers to any amino acid; finally, the engineered bacteriophage is directionally coupled to the Ni < 2 + >-IDA magnetic bead through the action of Ni-6His, and then the universal and novel immunoaffinity magnetic bead is formed. The universal and replaceable immunoaffinity magnetic bead prepared by the method can be used for preparing a chemical detection reagent, and can also be used for capturing, releasing and sensing detection of cells and extracellular vesicles.

The invention provides a virulent bacteriophage and application thereof, the virulent bacteriophage is named as vBVpaPChan1 and has been preserved in China Center for Type Culture Collection on December 10, 2024, the preservation address is Wuhan University, Wuhan, Hubei, China, and the preservation number is CCTCC M 20242772. The bacteriophage is safe, environmentally friendly and free of toxic and side effects, and compared with known bacteriophages, the bacteriophage is short in incubation period, large in outbreak amount and capable of effectively killing diseases caused by vibrio parahaemolyticus chan02.

The invention discloses a virulent bacteriophage vBValSR36H with a host being vibrio alginolyticus and application of the virulent bacteriophage vBValSR36H, and relates to the technical field of microbial control. The invention provides a bacteriophage capable of efficiently cracking Vibrio alginolyticus ATCC 17749T, the bacteriophage is named as vBValSR36H, the preservation number is 66248-B1, and the preservation address is Institute of Microbiology, Academy of Sciences in Guangdong Province. The vibrio alginolyticus bacteriophage vBValSR36H provided by the invention has good environmental stability and certain bactericidal activity, and has a relatively wide environmental adaptation range and relatively long survival time. The bacteriophage vBValSR36H provided by the invention can specifically and effectively kill, prevent and control related vibrio diseases, meanwhile, virulence factor genes and drug-resistant genes are not detected in the bacteriophage, and the bacteriophage vBValSR36H has the advantages of no toxic or side effect, high safety, environmental friendliness and wide application prospect. Therefore, the vibrio alginolyticus bacteriophage vBValSR36H can be completely applied to killing and / or preventing vibrio alginolyticus for non-disease diagnosis and treatment purposes.

The invention discloses a broad-spectrum lytic bacteriophage for preventing and controlling various vibrio infections in an aquaculture environment. The invention relates to V.alginolyticus phage vBValM-R37J, which is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on August 6, 2025, the address is No.100 Courtyard, Xianlie Middle Road, Xianlie District, Guangzhou City, Guangdong Province, the postcode is 510070, and the preservation number is GDMCC NO.66813-B1. The invention further discloses a method for preparing the V.alginolyticus phage vBValM-R37J strain. The bacteriophage R37J is a candidate therapeutic bacteriophage with wide host spectrum, high splitting efficiency, gene safety and environmental stability, and has the potential of being popularized and applied in aquaculture as a novel biological tool for accurately preventing and controlling various vibrio infections. A new biological resource is provided for accurate prevention and control of aquatic pathogenic bacteria, and a theoretical basis and a technical support are provided for popularization and application of a phage therapy in an actual culture system.

The invention relates to the technical field of microorganisms, in particular to nocardia seriolae bacteriophage as well as a composition and application thereof. The name of the nocardia seriolae bacteriophage is RDP-NS002, the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025, and the preservation number of the nocardia seriolae bacteriophage is CGMCC No.46674. The nocardia seriolae bacteriophage is named as RDP-NS002, and the nocardia seriolae bacteriophage is preserved in the China General Microbiological Culture Collection Center on August 25, 2025. The composition comprises the bacteriophage. The bacteriophage or the composition is prepared in the following steps: (1) preparing a product for killing nocardia seriolae; (2) preparing a product for inhibiting nocardia seriola; and (3) application in preparation of a product for preventing and / or treating fish nocardia disease caused by nocardia seriolae. The phage has the characteristics of high thermal stability, high acid-base stability and high splitting rate, has a long-acting inhibition effect, and is beneficial to prevention and treatment of nocardia seriola diseases.

Strategies, systems, methods, reagents, and kits for phage-assisted continuous evolution are provided herein. These include strategies, systems, methods, reagents, and kits allowing for stringency modulation to evolve weakly active or inactive biomolecule variants, negative selection of undesired properties, and / or positive selection of desired properties.

Provided are a method for controlling a soilborne disease in which a load on an environment and a human body is reduced, and a novel predatory bacterium therefor.　Provided are: a predatory bacterium or a variant thereof selected from the group consisting of bacteria of the genus Bacteriovorax and bacteria of the genus Bdellovibrio which selectively prey on a pathogenic bacterium belonging to the family Burkholderiaceae, the family Pectobacteriaceae, or the family Lysobacteraceae; a method for controlling a soilborne plant disease caused by the pathogenic bacterium, the method characterized in that the predatory bacterium or variant thereof is applied to a seed, root, or underground stem of a plant, rhizosphere soil, or soil; and a composition.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention discloses a bacteriophage host prediction method based on a weighted integrated convolutional neural network. The method comprises the following steps: obtaining a joint feature vector for an input bacteriophage protein sequence and a host receptor protein sequence; taking the bacteriophage-host pair as a positive sample, randomly selecting non-host bacteria for each bacteriophage to generate a negative sample, dividing the negative sample into M subsets, and combining each subset with all the positive samples to form M balance training subsets; for each balance training subset, training an independent one-dimensional convolutional neural network model; independently training a one-dimensional convolutional neural network sub-model for each balance training subset to obtain a plurality of sub-models with different performances; and distributing weights based on the performance indexes of the sub-models on the verification set, performing weighted fusion on the prediction probabilities of the M sub-models, and outputting a final host interaction probability. The method realizes accurate prediction of phage-host interaction on the premise of only needing basic sequence information, and has the advantages of light weight, high efficiency and wide applicability.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention relates to a preparation method of an efficient antibacterial material based on bionic design. The method comprises the following steps: step A, synthesizing a piezoelectric antibacterial material; and step B, combining the piezoelectric antibacterial material and a targeting material through a liposome carrier to prepare a bionic bacteriophage. According to the scheme, an innovative bionic bacteriophage concept is provided, a simple and intelligent antibacterial system is developed, reactive oxygen species (ROS) in a bacterial microenvironment is stimulated to be improved through energy conversion, bacterial cell membranes, protein and DNA are destroyed, and therefore antibacterial treatment is carried out.

The invention relates to the technical field of feed ingredient optimization, in particular to an ingredient optimization and adjustment system for a phage type antibiotic-free feed additive. Comprising the following steps: acquiring multi-dimensional environmental data and antibody content indexes and stress state information of individuals; determining a health index according to the antibody content index and the stress state information; performing batching delay analysis according to the change of the health index, and determining a lag moment; determining an effect coefficient in combination with the lagging time and the health index, determining the influence degree of the environmental data of each dimension on the batching effect, and screening to obtain an influence environmental dimension in combination with the influence degree of the environmental data of all dimensions on the batching effect and the predicted value of the environmental data in the next batch; and adjusting the ratio of additives in the same feeding stage in the next batch based on the influence environment dimension. According to the method, the ingredient adjustment logic can be optimized, and the adaptability of ingredients in a multi-dimensional complex scene is improved.

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The invention discloses a recombinant fusion protein of a human lambda light-chain single-chain antibody, a DNA (deoxyribonucleic acid) molecule, a library building method and application, and the recombinant fusion protein of the human lambda light-chain single-chain antibody is the recombinant fusion protein formed by connecting the human lambda light-chain single-chain antibody, phage Piii protein and luciferase, the amino acid sequence of the recombinant fusion protein of the human lambda light-chain single-chain antibody is shown as SEQ ID NO: 5, the recombinant fusion protein library of the human lambda light-chain single-chain antibody has large capacity, the established single-chain antibody TG1 library is more than 1 * 10 < 9 > cfu / mL, positive clones capable of being combined with ligands can be screened and enriched for multiple rounds, and the recombinant fusion protein library has the characteristics of high sensitivity, high signal-to-noise ratio and the like.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention discloses application of acinetobacter baumannii bacteriophage depolymerases in preparation of bacteriostatic agents, and relates to the technical field of biology. The depolymerases disclosed by the invention can inhibit the growth of a plurality of acinetobacter baumannii, have a bacteriostatic effect on the acinetobacter baumannii, and lay a foundation for developing effective infection control strategies and treatment methods to resist infection of the multi-drug-resistant acinetobacter baumannii.

The invention discloses a rapid and accurate detection method for pathogenic bacteria. The method comprises the following steps: immobilizing bacteriophages on the surfaces of magnetic nanoparticles through physical adsorption or chemical reaction, selectively enriching pathogenic bacteria in a complex sample by adopting the bacteriophage functionalized magnetic nanoparticles, quickly cracking the pathogenic bacteria on the surfaces of the magnetic nanoparticles by using CTAB (cetyltrimethyl ammonium bromide), releasing ATP in the bacteria, and quantitatively analyzing ATP by using bioluminescence. Further calculating the content of the pathogenic bacteria; the detection method is free of enrichment and amplification, can complete capture, enrichment and detection of pathogenic bacteria within 20 minutes, and can specifically detect viable bacteria of target bacteria in various complex matrix (such as food) samples due to the fact that bacteriophages are adopted as recognition molecules.

The invention belongs to the technical field of microorganisms, and discloses a high-temperature-resistant vibrio alginolyticus bacteriophage and a composition and application thereof, the high-temperature-resistant vibrio alginolyticus bacteriophage is named as vibrio alginolyticus bacteriophage PJ644 and is preserved in China General Microbiological Culture Collection Center on August 16, 2024, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.9624. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No. The bacteriophage has excellent high temperature resistance, and the bacteriophage and the bacteriophage composition not only can effectively prevent and treat various vibrio infections, but also can be used as active ingredients for preparing bacteriophage pharmaceutical preparations, aquatic feed additives, water disinfectants and aquatic product preservatives, and are used for effectively preventing and treating diseases caused by vibrio infections in aquaculture farms. The use is safe, and the problems of antibiotic residues and pathogen drug resistance caused by use of antibiotics are effectively avoided.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.

The invention discloses two mycobacterium bacteriophages and application thereof. The two bacteriophages both have a splitting spectrum width and efficient splitting capability, can specifically realize effective splitting of mycobacteria of five specific sequence types, and are further applied to the field of prevention and control of mycobacteria. Specifically, the bacteriophage MP2435 and the bacteriophage MP2451 not only can effectively inhibit the proliferation process of mycobacteria and block the formation of a biofilm of the mycobacteria, but also can efficiently kill the mycobacteria in a milk matrix; meanwhile, the two bacteriophages can still keep relatively high activity under the conditions that the temperature is 37-65 DEG C and the pH value is 3-12, and the bactericidal activity of the bacteriophages can be stably maintained even in acid-base, high-temperature and ultraviolet-containing extreme environments. Through the characteristics, the application scene and application range of the bacteriophage in mycobacterium prevention and control are remarkably widened, and an efficient and stable novel technical means is provided for biological prevention and control of mycobacterium.

The invention discloses a bacteriophage defense system as well as a construction method and application of the bacteriophage defense system in anti-bacteriophage engineering bacteria. The bacteriophage defense system is derived from Escherichia coli Nissle 1917, and comprises proteins as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, and derived proteins of the proteins as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. According to the invention, a Type II restriction-modification system with strong bacteriophage defense capability is identified from Escherichia coli Nissle 1917, and the Type II restriction-modification system is transplanted into strains such as Escherichia coli W3110, MG1655 (DE3), BL21 (DE3) and the like, so that the strains are endowed with superstrong bacteriophage resistance. The system is successfully applied to industrial engineering bacteria for producing ectoine, fine glufosinate-ammonium, ergothioneine and other products, and the bacteriophage defense capability of the industrial engineering bacteria is effectively enhanced on the basis that the production capacity of the industrial engineering bacteria is not seriously influenced.

The invention discloses a vibrio cantoniensis bacteriophage vBVcaSR45Z and an application of the vibrio cantoniensis bacteriophage The invention relates to Vibrio campbelli phage vBVcaSR45Z, which is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on December 8, 2025, the address is Courtyard 100 #, Xianlie Middle Road, Xiaolian District, Guangzhou City, Guangdong Province, the postcode is 510070, and the preservation number is GDMCC NO. 67441-B1. The invention further discloses a preparation method of the Vibrio campbelli phage vBVcaSR45Z strain. The bacteriophage vBVcaSR45Z has the advantages of rapid splitting capacity, high host inhibition effect, safe genome structure and clear systematic classification status, and provides an important basis for the bacteriophage vBVcaSR45Z as a biological prevention and control factor of aquatic vibrio pathogens.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS135 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS135. The human neutralizing antibody specifically aiming at the F protein of the respiratory syncytial virus is successfully obtained by applying a phage antibody library technology; the obtained human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody variable region gene, Fab antibody gene and full antibody gene under the characteristics of each antibody gene are utilized to obtain the human neutralizing anti-respiratory syncytial virus F protein gene engineering antibody. The antibody can be expressed and produced in prokaryotic cells, yeast cells, eukaryotic cells and any recombination system or any other reconstructed gene containing the antibody gene on the basis of the antibody, and an antibody product capable of neutralizing respiratory syncytial virus infection is obtained. And a specific antibody drug for clinically preventing and treating respiratory syncytial virus infection is prepared.

The invention discloses a monoclonal antibody H2 specifically bound with a lung cancer marker CYFRA21-1 and application, and relates to the technical field of biological medicines. The method comprises the following steps: firstly, screening from a Tomlinson I + J phage library by utilizing a phage display technology to obtain a lung cancer marker CYFRA21-1 monoclonal antibody H2, and the antibody has a heavy chain complementary determining region and a light chain complementary determining region which are formed by novel amino acid sequences and can be specifically combined with CYFRA21-1 protein; the monoclonal antibody H2 of the lung cancer marker CYFRA21-1 has the characteristics of high affinity, high specificity, stability and the like, and the monoclonal antibody H2 of the lung cancer marker CYFRA21-1 not only can efficiently and accurately detect the concentration of CYFRA21-1 protein, but also can be used for immunostaining of lung cancer tumor cells and lung cancer tissues in pathological diagnosis, and has important significance for detecting the concentration of CYFRA21-1.

The invention provides a targeted mutation system based on orthogonal bacteriophage RNA polymerase and an orthogonal transcription mutant. According to the orthogonal transcription mutants, phage RNA polymerase and deaminase are fused, and a large number of mutations can be rapidly and efficiently generated on a target gene. The bacteriophage RNA polymerase part of the orthogonal transcription mutants can specifically recognize corresponding promoters and transcribe downstream genes, and the deaminase part of the bacteriophage RNA polymerase part of the orthogonal transcription mutants can generate mutation in the transcription process. The optimized orthogonal transcription mutants can simultaneously generate mutation from C: G to T: A and mutation from A: T to G: C on a target gene. According to the method, mutation and screening can be carried out on target genes on plasmids or genomes or genes on metabolic pathways, the evolution efficiency of enzymes or other proteins can be greatly improved, and time and cost are saved.

The invention provides a ginger planting method for preventing and treating ginger bacterial wilt, and belongs to the technical field of ginger planting.According to the ginger planting method, through crop rotation, a ginger bacterial wilt pathogenic bacterium host chain is effectively cut off, ralstonia solanacearum is inhibited, harmful pathogenic bacteria in soil are removed through sun exposure, a biochar-probiotic mixture is applied, and meanwhile the harmful pathogenic bacteria in the soil are inhibited; biochar is utilized to increase porosity and water-holding capacity, relieve the problem of soil hardening, increase the pH value of soil, increase the content of alkaline cations, effectively inhibit growth of pathogenic bacteria of ginger blast, and also adsorb and retain nutrients such as ammonium and potassium through static electricity, and the pore structure of the biochar provides a shelter for probiotic groups, so that the probiotic groups are planted in the soil, and the soil quality is improved. The living space of the ginger blast pathogenic bacteria is inhibited; seed gingers are soaked in bacterium liquid containing bacteriophages, ginger blast pathogenic bacteria are effectively inhibited, drip irrigation is adopted for later-period management to maintain soil humidity, reproduction and spreading of the ginger blast pathogenic bacteria are effectively prevented and controlled, charcoal base fertilizer is additionally applied, and finally ginger blast is effectively prevented and controlled.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.